Y.K. Shen

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

A. Armstrong, K. Reich, P. Foley, 2017, Journal of the American Academy of Dermatology.

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

C. Griffiths, P. Foley, K. Gordon, 2018, The British journal of dermatology.

Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

M. Lebwohl, K. Reich, M. Song, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2 *

A. Armstrong, C. Griffiths, K. Reich, 2021, The British journal of dermatology.